Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
A phase II study of dianhydrogalactitol in patients with advanced lung cancer yielded responses in three of 33 patients with adenocarcinoma and in one of 11 patients with large cell anaplastic carcinoma. Small cell and squamous cell carcinomas were unresponsive. Toxic effects were acceptable and were related to serum creatinine values.
D000230:Adenocarcinoma / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D003961:Dianhydrogalactitol / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D013402:Sugar Alcohols / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D013402:Sugar Alcohols; D003961:Dianhydrogalactitol